At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
AG200-15drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic Study of the Agile TCDS AG200-15 Following Weekly Application to Three Anatomical Sites (Abdomen, Buttock and Upper Torso) in Healthy Female Volunteers
In Brief
A Phase 1 clinical trial evaluating AG200-15 for Healthy. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This is a pharmacokinetics and safety study over 3 weekly applications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
Primary CompletionApr 2011
First PostedAug 2011
TodayJul 2026
First PostedAug 23, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.9 years ago
Interventions
AG200-15drug
A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.